# ALEC — Alector Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALEC  
**Sources:** 23  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alec-alector-inc-catalysts-narrative-risks-5972

---

## Snapshot (as of Oct 2, 2026)

Alector Inc. (NASDAQ: ALEC) closed at ~$1.81, down 2.69% that session, with a market cap of ~$202M and a 52-week range of $1.09–$3.40 [[21]](https://stockanalysis.com/stocks/alec/), [[22]](https://stockanalysis.com/stocks/alec/), [[23]](https://finance.yahoo.com/quote/ALEC/). This matches the on-file data (healthcare/biotechnology, ~$206.57M market cap) [[20]](https://finance.yahoo.com/quote/ALEC/), [[23]](https://finance.yahoo.com/quote/ALEC/). The company is a clinical-stage biotech building its strategy around the Alector Brain Carrier (ABC) blood-brain barrier platform [[24]](https://www.alector.com/).

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alec-alector-inc-catalysts-narrative-risks-5972 (free to sign up)._
